200 related articles for article (PubMed ID: 28451811)
1. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
[TBL] [Abstract][Full Text] [Related]
2. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
[TBL] [Abstract][Full Text] [Related]
4. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Delcath Systems' Generation 2 (GEN 2) melphalan hemofiltration system in a porcine model of percutaneous hepatic perfusion.
Moeslein FM; McAndrew EG; Appling WM; Hryniewich NE; Jarvis KD; Markos SM; Sheets TP; Uzgare RP; Johnston DS
Cardiovasc Intervent Radiol; 2014 Jun; 37(3):763-9. PubMed ID: 24402644
[TBL] [Abstract][Full Text] [Related]
6. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
[TBL] [Abstract][Full Text] [Related]
7. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
[TBL] [Abstract][Full Text] [Related]
8. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
[TBL] [Abstract][Full Text] [Related]
9. Isolated hypoxic hepatic perfusion with melphalan in patients with irresectable ocular melanoma metastases.
van Etten B; de Wilt JH; Brunstein F; Eggermont AM; Verhoef C
Eur J Surg Oncol; 2009 May; 35(5):539-45. PubMed ID: 18760560
[TBL] [Abstract][Full Text] [Related]
10. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
[TBL] [Abstract][Full Text] [Related]
11. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
Meijer TS; Burgmans MC; de Leede EM; de Geus-Oei LF; Boekestijn B; Handgraaf HJM; Hilling DE; Lutjeboer J; Vuijk J; Martini CH; van Erkel AR; van der Meer RW; Tijl FGJ; Speetjens FM; Kapiteijn E; Vahrmeijer AL
Ann Surg Oncol; 2021 Feb; 28(2):1130-1141. PubMed ID: 32761328
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.
Pingpank JF; Libutti SK; Chang R; Wood BJ; Neeman Z; Kam AW; Figg WD; Zhai S; Beresneva T; Seidel GD; Alexander HR
J Clin Oncol; 2005 May; 23(15):3465-74. PubMed ID: 15908655
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
[TBL] [Abstract][Full Text] [Related]
14. Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: A phase I study.
van Iersel LB; de Leede EM; Vahrmeijer AL; Tijl FG; den Hartigh J; Kuppen PJ; Hartgrink HH; Gelderblom H; Nortier JW; Tollenaar RA; van de Velde CJ
Eur J Surg Oncol; 2014 Nov; 40(11):1557-63. PubMed ID: 25125340
[TBL] [Abstract][Full Text] [Related]
15. Use of partial venovenous cardiopulmonary bypass in percutaneous hepatic perfusion for patients with diffuse, isolated liver metastases: a case series.
Fitzpatrick M; Richard Alexander H; Deshpande SP; Martz DG; McCormick B; Grigore AM
J Cardiothorac Vasc Anesth; 2014 Jun; 28(3):647-51. PubMed ID: 24290749
[TBL] [Abstract][Full Text] [Related]
16. Isolated hypoxic hepatic perfusion with retrograde outflow in patients with irresectable liver metastases; a new simplified technique in isolated hepatic perfusion.
Verhoef C; de Wilt JH; Brunstein F; Marinelli AW; van Etten B; Vermaas M; Guetens G; de Boeck G; de Bruijn EA; Eggermont AM
Ann Surg Oncol; 2008 May; 15(5):1367-74. PubMed ID: 18239976
[TBL] [Abstract][Full Text] [Related]
17. Predictive Parameters in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan for Unresectable Liver Metastases from Uveal Melanoma: A Retrospective Pooled Analysis.
Tong TML; Samim M; Kapiteijn E; Meijer TS; Speetjens FM; Brüning R; Schroeder TH; El-Sanosy S; Maschke H; Wacker FK; Vogel A; Dewald CLA; Goeman JJ; Burgmans MC
Cardiovasc Intervent Radiol; 2022 Sep; 45(9):1304-1313. PubMed ID: 35922562
[TBL] [Abstract][Full Text] [Related]
18. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
[TBL] [Abstract][Full Text] [Related]
19. A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
Alexander HR; Libutti SK; Bartlett DL; Puhlmann M; Fraker DL; Bachenheimer LC
Clin Cancer Res; 2000 Aug; 6(8):3062-70. PubMed ID: 10955785
[TBL] [Abstract][Full Text] [Related]
20. Percutaneous Isolated Hepatic Perfusion as a Treatment for Isolated Hepatic Metastases of Uveal Melanoma: Patient Outcome and Safety in a Multi-centre Study.
Vogl TJ; Koch SA; Lotz G; Gebauer B; Willinek W; Engelke C; Brüning R; Zeile M; Wacker F; Vogel A; Radeleff B; Scholtz JE
Cardiovasc Intervent Radiol; 2017 Jun; 40(6):864-872. PubMed ID: 28144756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]